contingent value right – Talk Bio

Actionable Insights Powered by AI

Alkermes Ups Bid for Avadel Amid Lundbeck’s Competing Offer in Narcolepsy Drug Takeover Battle

2 months ago talkbio0Tagged Acquisition, Alkermes, Avadel Pharmaceuticals, bidding war, contingent value right, LUMRYZ, Lundbeck, M&A, Narcolepsy, Pharma, Primary Hypersomnia

Alkermes; Avadel Pharmaceuticals; Lundbeck; bidding war; Lumryz; narcolepsy; acquisition; contingent value right; pharma M&A; idiopathic hypersomnia

Novo Nordisk Ups the Stakes With $10B Bid for Metsera, Surpassing Pfizer’s Offer

2 months ago talkbio0Tagged antitrust litigation, bidding war, contingent value right, Drug Industry, Metsera, Novo Nordisk, Pfizer

Novo Nordisk; Pfizer; Metsera; bidding war; acquisition; $10 billion; contingent value right; pharmaceutical industry; antitrust litigation

Novo Nordisk Ups Metsera Bid to $10 Billion to Top Pfizer’s Offer

2 months ago talkbio0Tagged Acquisition, contingent value right, Diabetes, M&A, Metsera, Novo Nordisk, Obesity, Pfizer

Novo Nordisk; Metsera; Pfizer; M&A; biotech acquisition; contingent value right; obesity drugs; diabetes treatments

Bluebird Private Equity Buyout Boosts Upfront Cash for Shareholders

8 months ago talkbio0Tagged Capital, Carlyle, contingent value right, CVR, DKK1 gene, Family Turdidae (organism), Merger, Private Equity, shareholders, upfront cash

Bluebird; private equity buyout; shareholders; upfront cash; Carlyle; SK Capital; contingent value right; CVR; buyout terms; merger